A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration
A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration since planting roots in the Queen City, and officials said the deal will help fuel faster international growth.
Orange Grove Bio, a preclinical drug investment and development firm based at University of Cincinnati’s 1819 Innovation Hub, announced a new partnership Tuesday with SV Investment, a Seoul, Korea-based venture capital and private equity firm. The companies said the partnership will allow them to collaborate on jointly sourcing and developing new therapeutics in the U.S. and East Asia.
Michigan BioSocial Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
January 25, 2020
IF HENRY FORD WERE IN BIOTECH
IF HENRY FORD WERE IN BIOTECH Please join us to hear from our CEO, Marc Appel.
July 30, 2024
Genexys BioMed Awarded $320K SBIR Grant to Advance Novel Cystic Fibrosis Gene Therapy
NIH Grant to Accelerate Development of Innovative Non-Viral, Non-Lipid Platform Originating from Cincinnati Children’s CINCINNATI, Ohio, July 30, 2024 — Genexys BioMed, a pre-clinical stage biotechnology company developing a novel non-viral, non-lipid genetic medicine platform for the treatment of cystic fibrosis (CF) and other genetic diseases, announced today it has been awarded a $320,000 Phase
February 9, 2022
Leading Korean VC partners with USA’s Orange Grove
Orange Grove Bio, a USA-based pre-clinical drug investment and development firm, and SV Investment, a South Korea-based venture capital and private equity firm, today announced the establishment of a new partnership through which the companies will collaborate on jointly sourcing and developing novel therapeutics in the USA and Korea. As priority partners, the companies will cultivate the US and Korean biotech landscape through technology licensing and company creation in their respective geographic areas. Under terms of the partnership, SV Investment will leverage its relationships with biotech companies and academic institutions in Korea to identify licensing opportunities for promising early-stage research in the area of drug development. As part of the agreement, Marc Appel, chief executive of Orange Grove, will join SV Investment as a venture partner and will play a key role in evaluating the licensing opportunities that are identified at Korean biotech companies and universities. As appropriate, Orange Grove will work to license these technologies as a basis for life science company creation in the USA, with SV Investment serving as an early-stage investor in the companies.
November 17, 2021
The University of Pittsburgh and Orange Grove Bio Establish Partnership …
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration “Orange Grove Bio, a preclinical drug investment and development firm, and
July 23, 2024
Orange Grove Bio and University of Chicago Form Strategic Partnership to Accelerate Biotech Innovation and Commercialization
Collaboration Aims to Bridge the Gap Between Academic Research and Commercial Development, Fostering a Thriving Biotech Ecosystem in Chicago CINCINNATI, Ohio, July 23, 2024 — Orange Grove Bio, a leading integrated biopharmaceutical company, and the University of Chicago’s Polsky Center for Entrepreneurship and Innovation today announced a strategic partnership to catalyze the successful commercialization of
January 25, 2020
Orange Grove Bio: Filling the Gap in Preclinical Drug Development
Orange Grove Bio is a preclinical drug development company focused on driving down the cost of drug development… Orange Grove Bio, a preclinical drug investment and development firm, and the University of Pittsburgh today announced the establishment of a collaboration Orange Grove Bio is a preclinical drug development company focused on driving down the cost
January 25, 2020
How to Invest in Biotech Series – Phases, Stages, and Pitfalls
Emily Whitehead was 5 years old when she was diagnosed with acute lymphoblastic leukemia… Her cancer was resistant to traditional treatments and her prognosis was poor. In a final effort to save their daughter, her parents enrolled her in a clinical trial study at Children’s Hospital of Philadelphia for a new type of therapy called
November 17, 2021
Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine
Orange Grove Bio Establishes Partnership with Albert Einstein College of Medicine The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration and growth “Orange Grove Bio, AlleyCorp and Alexandria Venture Investments, three industry leaders dedicated to the acceleration
